Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of JS016 in Hospitalized COVID-19 Patients
NCT04931238Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of etesevimab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Clinical status at 28 days. Status: unknown.
02
Drugs
etesevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04931238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931238.